Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201.
The organization of the sphingosine 1-phosphate signaling system.
Fatigue is associated with poor sleep in people with multiple sclerosis and cognitive impairment.
FDA Approves New Drug to Treat Psoriasis
Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations.
Teriflunomide for oral therapy in multiple sclerosis.
Attenuation of corpus callosum axon myelination and remyelination in the absence of circulating sex hormones.
Using the random forest method to detect a response shift in the quality of life of multiple sclerosis patients: a cohort study.
Cerebrospinal fluid and urinary biomarkers in multiple sclerosis.
Toxoplasmosis and Polygenic Disease Susceptibility Genes: Extensive Toxoplasma gondii Host/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders.
Sphingosine 1-phosphate receptor agonists: a patent review (2010 - 2012).
Amyloid fibril formation and chaperone-like activity of peptides from alphaA-crystallin.
A new therapeutic target for the treatment of multiple sclerosis.
Blood-Brain Barrier Disruption is More Severe in Neuromyelitis Optica than in Multiple Sclerosis and Correlates with Clinical Disability.
A case of Guillain-Barré syndrome with meningeal irritation.
In vivo imaging of activated microglia in a mouse model of focal cerebral ischemia by two-photon microscopy.
Enhanced Neuroprotective Effects of Combination Therapy with Bone Marrow-Derived Mesenchymal Stem Cells and Ginkgo biloba Extract (EGb761) in a Rat Model of Experimental Autoimmune Encephalomyelitis.
SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease.
Longitudinal association between depressive symptoms and walking impairment in people with relapsing-remitting multiple sclerosis.
Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study.
Protective Effect of a cAMP Analogue on Behavioral Deficits and Neuropathological Changes in Cuprizone Model of Demyelination.
Does Slowed Processing Speed Account for Executive Deficits in Multiple Sclerosis? Evidence From Neuropsychological Performance and Structural Neuroimaging.
The primary vascular dysregulation syndrome: implications for eye diseases.
Cognition and eye movements: assessment of cerebral dysfunction.
Translocator Protein 18 kDa (TSPO) Expression in Multiple Sclerosis Patients.

Pages